Oleg Gluz, MD, discusses results from the phase 2 WSG-TP-II trial which investigated survival outcomes with neoadjuvant endocrine therapy plus trastuzumab and pertuzumab vs de-escalated chemotherapy plus trastuzumab and pertuzumab in...
Oleg Gluz, MD, discusses results from the phase 2 WSG-TP-II trial which investigated survival outcomes with neoadjuvant endocrine therapy plus trastuzumab and pertuzumab vs de-escalated chemotherapy plus trastuzumab and pertuzumab in...
Oleg Gluz, MD, discusses results...